Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W, Quanquan S, Chuner J, Lei W, Fengqin Y, Zhimin Y, Tongxin L, Min X, Peng W, Haitao J, Aizawa R, Sakamoto M, Yuezhen W, Zhenfu F. Fangzheng W, et al. Among authors: aizawa r. Oncotarget. 2017 May 27;8(57):96798-96808. doi: 10.18632/oncotarget.18245. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228572 Free PMC article.
Addition of 5-fluorouracil to first-line induction chemotherapy with docetaxel and cisplatin before concurrent chemoradiotherapy does not improve survival in locoregionally advanced nasopharyngeal carcinoma.
Fangzheng W, Chuner J, Lei W, Fengqin Y, Zhimin Y, Quanquan S, Tongxin L, Min X, Peng W, Bin L, Aizawa R, Sakamoto M, Zhenfu F. Fangzheng W, et al. Among authors: aizawa r. Oncotarget. 2017 Aug 7;8(53):91150-91161. doi: 10.18632/oncotarget.20017. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207632 Free PMC article.
Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Aizawa R, et al. Int J Clin Oncol. 2019 Oct;24(10):1247-1255. doi: 10.1007/s10147-019-01478-y. Epub 2019 May 31. Int J Clin Oncol. 2019. PMID: 31152322 Free PMC article.
Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T. Aizawa R, et al. Int J Clin Oncol. 2020 Apr;25(4):713-719. doi: 10.1007/s10147-019-01596-7. Epub 2019 Dec 9. Int J Clin Oncol. 2020. PMID: 31820209 Free article. Clinical Trial.
95 results